Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Public ClinicalTrials.gov record NCT04329949. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.
Study identification
- NCT ID
- NCT04329949
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 43 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2020 (Actual)
- Primary completion
- Aug 23, 2021 (Actual)
- Completion
- Mar 25, 2022 (Actual)
- Last update posted
- Nov 18, 2023
2020 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site #038 | Scottsdale | Arizona | 85258 | — |
| Site #171 | Duarte | California | 91010 | — |
| Site #076 | Los Angeles | California | 90095 | — |
| Site #032 | Aurora | Colorado | 80045 | — |
| Site #009 | Atlanta | Georgia | 30322 | — |
| Site #184 | Goshen | Indiana | 46526 | — |
| Site #065 | Baltimore | Maryland | 21231 | — |
| Site #058 | Detroit | Michigan | 48201 | — |
| Site #185 | Omaha | Nebraska | 68114 | — |
| Site #182 | Buffalo | New York | 14263 | — |
| Site #044 | New York | New York | 10016 | — |
| Site #222 | New York | New York | 10016 | — |
| Site #077 | Columbus | Ohio | 43210 | — |
| Site #186 | Toledo | Ohio | 43614 | — |
| Site #172 | Pittsburgh | Pennsylvania | 15232 | — |
| Site #175 | Knoxville | Tennessee | 37920 | — |
| Site #176 | Nashville | Tennessee | 37232 | — |
| Site #173 | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04329949, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2023 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04329949 live on ClinicalTrials.gov.